Boston Therapeutics Initiates Phase IIb Study to Assess the Efficacy and Safety of SUGARDOWN(R) for Type 2 Diabetes
29 mai 2014 07h00 HE
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - May 29, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE), a leading developer of compounds that address diabetes using complex carbohydrate chemistry, has initiated a...
Boston Therapeutics to Present at SeeThruEquity Microcap Investor Conference on May 28 and Marcum Microcap Conference on May 29
27 mai 2014 08h01 HE
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - May 27, 2014) - Boston Therapeutics, Inc. (BTI) (OTCQB: BTHE), a leading developer of compounds that address diabetes using complex carbohydrate chemistry, today...
Boston Therapeutics Announces Strategic Marketing Agreement With Benchworks SD Aimed at Growing Sales of SUGARDOWN(R)
20 mai 2014 07h00 HE
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - May 20, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE) a leading developer of compounds that address blood sugar management and inflammatory disease using complex...
Boston Therapeutics Reports Corporate Update and Financial Results for the First Quarter Ended March 31, 2014
13 mai 2014 12h22 HE
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - May 13, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a leading developer of compounds that address diabetes using...
Boston Therapeutics Signs Agreement With Patheon to Manufacture Pharmaceutical-Grade BTI-320 Tablets
06 mai 2014 07h00 HE
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - May 6, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE), a clinical stage developer of innovator compounds that address diabetes and inflammatory diseases using complex...
Boston Therapeutics to Present Late-Breaking Poster on Mechanism of Action for BTI-320 at AACE Annual Congress in Las Vegas on May 14-18
29 avr. 2014 06h15 HE
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - Apr 29, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE), a clinical stage developer of innovative compounds that address diabetes and inflammatory diseases using...
Boston Therapeutics Reports Corporate Update and Financial Results for the Fourth Quarter and Year Ended December 31, 2013
17 mars 2014 07h00 HE
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - Mar 17, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a leading developer of compounds that address diabetes...
Boston Therapeutics to Initiate a Phase II Clinical Study of BTI-320 in U.S.
04 mars 2014 07h18 HE
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - Mar 4, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), an innovative developer of compounds that address diabetes using...
Boston Therapeutics Appoints Larry K. Ellingson, Former Chair of the American Diabetes Association, as Chair of Its Scientific Advisory Board
25 févr. 2014 07h00 HE
|
Boston Therapeutics, Inc.
MANCHESTER, NH--(Marketwired - Feb 25, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), an innovative developer of drugs that address diabetes using complex...
Boston Therapeutics Signs Agreement to Market SugarDown(R) in the U.S.
11 févr. 2014 07h00 HE
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - Feb 11, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), an innovative developer of drugs that address diabetes using complex...